Elite Pharmaceuticals, Inc. Gain (Loss) on Sale of Derivatives
Elite Pharmaceuticals, Inc. (ELTP) reported Gain (Loss) on Sale of Derivatives of $94.25 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfDerivatives · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for the quarter ending 2026-06-30 was $94.25K.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for the quarter ending 2025-06-30 was -$22.11M.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for the quarter ending 2016-06-30 was $2.40M, a 66.73% decline year-over-year.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for the quarter ending 2015-06-30 was $7.21M.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for fiscal 2026 was $7.86M.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for fiscal 2025 was -$18.90M.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for fiscal 2016 was $7.39M, a 63.65% decline from fiscal 2015.
- Elite Pharmaceuticals, Inc. gain (loss) on sale of derivatives for fiscal 2015 was $20.34M.
| Period end | Gain (Loss) on Sale of Derivatives 3 month | Gain (Loss) on Sale of Derivatives 12 month |
|---|---|---|
| 2026-06-30 | $94.25K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $7.86M 10-K · filed 2026-06-29 | |
| 2025-06-30 | -$22.11M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$18.90M 10-K · filed 2026-06-29 | |
| 2016-06-30 | $2.40M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $7.39M 10-K · filed 2016-06-15 | |
| 2015-06-30 | $7.21M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $20.34M 10-K · filed 2016-06-15 | |
| 2014-03-31 | -$35.43M 10-K · filed 2016-06-15 |